Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Head & Neck 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 12Rectal Neoplasms 5Colonic Neoplasms 5Neoplasm Metastasis 2Carcinoma, Non-Small-Cell Lung 2Advanced Solid Tumors (Excluding Breast Cancer) 2Advanced Solid Tumors 2Urologic Diseases 1Stomach Neoplasms 1Sarcoma, Ewing 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Renal Insufficiency 1Refractory Solid Tumors 1Pretreated Metastatic Colorectal Cancer 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Liver Neoplasms 1Liver Diseases 1Kidney Neoplasms 1Kidney Diseases 1Head and Neck Neoplasms 1Gastric Adenocarcinoma 1Esophageal Neoplasms 1Carcinoma, Renal Cell 1Biliary Tract Neoplasms 1Advanced or Metastatic Solid Tumors 1Advanced Gastrointestinal Tumors 1

Interventions

Carboplatin 19Paclitaxel 18Fluorouracil 16Cisplatin 16pembrolizumab 15Radiotherapy 14Oxaliplatin 12Irinotecan 12Capecitabine 12Cyclophosphamide 10Radiation 8Leucovorin 8Docetaxel 8fludarabine 6Taxes 6Gemcitabine 6Trastuzumab 5fludarabine phosphate 4aldesleukin 4LY6K protein, human 4Fluorodeoxyglucose F18 4Erlotinib Hydrochloride 4Bevacizumab 4spartalizumab 3Surgical Procedures, Operative 3S 1 (combination) 3Pemetrexed 3Nivolumab 3Drug Therapy 3zimberelimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Esophageal Neoplasms × trifluridine tipiracil drug combination × Clear all
NCT04999761 2024-09-25

AB122 Platform Study

Taiho Pharmaceutical Co., Ltd.

Phase 1 Recruiting
917 enrolled
GastrointestinalHead & NeckSarcomaThoracic

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Sarcoma, Alveolar Soft Part

Data powered by HemOnc (CC BY 4.0) Colophon âš¡